Literature DB >> 31870830

Gut microbiota; an overlooked effect of phosphate binders.

Yalda Rahbar Saadat1, Bahram Niknafs2, Seyed Mahdi Hosseiniyan Khatibi2, Mohammadreza Ardalan2, Hasan Majdi3, Zahra Bahmanpoor4, Sima Abediazar2, Sepideh Zununi Vahed5.   

Abstract

Hyperphosphatemia is a mineral bone-disease that increases cardiovascular complications and all-cause mortality in chronic kidney disease (CKD) patients. Oral phosphate binders absorb the dietary phosphate to prevent its high plasma levels. Moreover, they can adsorb some uremic toxins and decrease inflammation. A few recent studies highlight an ignored effect of phosphate binders on gut microbiota. Phosphorous is a major nutrient for survival and reproduction of bacteria and its intestinal concentration may impact the activity and composition of the gut microbiota. CKD is a state of an altered gut microbiome and bacterial-derived uremic toxins stimulate cardiovascular disease and systemic inflammation. The identification of the impact of phosphate binders on gut opens a new era in nephrology and fill the existing gap in interpretation of beneficial effects of phosphate binders. This review aims to highlight the impact of oral phosphate binders on the gut microbiome in CKD.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Chronic kidney disease; ESRD; Hemodialysis; Hyperphosphatemia; Microbiome; Phosphorus; Uremic toxins

Mesh:

Substances:

Year:  2019        PMID: 31870830     DOI: 10.1016/j.ejphar.2019.172892

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  8 in total

1.  Gut microbiome in hemodialysis patients treated with calcium acetate or treated with sucroferric oxyhydroxide: a pilot study.

Authors:  Ana Merino-Ribas; Ricardo Araujo; Ioana Bancu; Fredzzia Graterol; Andrea Vergara; Marc Noguera-Julian; Roger Paredes; Jordi Bonal; Benedita Sampaio-Maia
Journal:  Int Urol Nephrol       Date:  2021-12-19       Impact factor: 2.266

Review 2.  Emerging cross-talks between chronic kidney disease-mineral and bone disorder (CKD-MBD) and malnutrition-inflammation complex syndrome (MICS) in patients receiving dialysis.

Authors:  Shunsuke Yamada; Kazuhiko Tsuruya; Takanari Kitazono; Toshiaki Nakano
Journal:  Clin Exp Nephrol       Date:  2022-03-30       Impact factor: 2.617

3.  Benefits of resistant starch type 2 for patients with end-stage renal disease under maintenance hemodialysis: a systematic review and meta-analysis.

Authors:  Linpei Jia; Xingtong Dong; Xiaoxia Li; Rufu Jia; Hong-Liang Zhang
Journal:  Int J Med Sci       Date:  2021-01-01       Impact factor: 3.738

Review 4.  Intestinal Chelators, Sorbants, and Gut-Derived Uremic Toxins.

Authors:  Solène M Laville; Ziad A Massy; Said Kamel; Jean Marc Chillon; Gabriel Choukroun; Sophie Liabeuf
Journal:  Toxins (Basel)       Date:  2021-01-26       Impact factor: 4.546

Review 5.  Contribution of Gut Microbiota-Derived Uremic Toxins to the Cardiovascular System Mineralization.

Authors:  Iwona Filipska; Agata Winiarska; Monika Knysak; Tomasz Stompór
Journal:  Toxins (Basel)       Date:  2021-04-10       Impact factor: 4.546

Review 6.  Phosphate, Microbiota and CKD.

Authors:  Chiara Favero; Sol Carriazo; Leticia Cuarental; Raul Fernandez-Prado; Elena Gomá-Garcés; Maria Vanessa Perez-Gomez; Alberto Ortiz; Beatriz Fernandez-Fernandez; Maria Dolores Sanchez-Niño
Journal:  Nutrients       Date:  2021-04-13       Impact factor: 5.717

7.  Comparative Gut Microbiome Differences between Ferric Citrate and Calcium Carbonate Phosphate Binders in Patients with End-Stage Kidney Disease.

Authors:  Ping-Hsun Wu; Po-Yu Liu; Yi-Wen Chiu; Wei-Chun Hung; Yi-Ting Lin; Ting-Yun Lin; Szu-Chun Hung; Rachel Ann Delicano; Mei-Chuan Kuo; Chun-Ying Wu
Journal:  Microorganisms       Date:  2020-12-20

Review 8.  Interplay between gut microbiota, bone health and vascular calcification in chronic kidney disease.

Authors:  Fernanda G Rodrigues; Milene S Ormanji; Ita P Heilberg; Stephan J L Bakker; Martin H de Borst
Journal:  Eur J Clin Invest       Date:  2021-06-07       Impact factor: 4.686

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.